Learn more about HLA technical and clinical advancements in transplant diagnostics.

Visit the Learning Center

2021 ISHLT | Innovations in Rejection Surveillance after Heart Transplant

For post-transplant management in heart patients, the endomyocardial biopsy is considered the gold standard to detect acute rejection. However, research has found that in biopsy assessments for rejection, concordance among expert pathologists is less than 67%. This presentation will explore case studies and the clinical use of novel technologies, including molecular diagnostic testing of intragraft mRNA transcripts and donor-derived cell-free DNA, for more accurate diagnosis of cellular and antibody-mediated rejection, acute rejection, and cardiac allograft vasculopathy (CAV). • Moderator: Dr. Christopher Lawrence, Director, Medical Affairs | Thermo Fisher Scientific • Guest Speaker: Jon A Kobashigawa, MD | Cedars-Sinai Medical Center, Los Angeles, California